Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 20/20 | 0.69 |
| ▸ | F2 | P00734 | 2/20 | 0.64 |
| ▸ | F9 | P00740 | 1/20 | 0.64 |
| ▸ | PLAT | P00750 | 1/20 | 0.64 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13303241 | 0.90 | F10 (0.69) | F10F2F9PLATKLKB1 | |
| SCHEMBL2857732 | 0.88 | F10 (0.76) | F10F2F9PLATKLKB1 | |
| SCHEMBL2864199 | 0.88 | F10 (0.75) | F10F2F9PLATKLKB1 | |
| SCHEMBL2859003 | 0.87 | F10 (0.71) | F10F2F9PLATKLKB1 | |
| SCHEMBL3534171 | 0.85 | F10 (0.71) | F10F2F9PLATKLKB1 | |
| SCHEMBL2862722 | 0.85 | F10 (0.76) | F10F2F9PLATKLKB1 | |
| SCHEMBL2860012 | 0.84 | F10 (0.72) | F10F2F9PLATKLKB1 | |
| SCHEMBL2855575 | 0.84 | F10 (0.79) | F10F2F9PLATKLKB1 | |
| SCHEMBL2853066 | 0.84 | F10 (0.65) | F10F2F9PLATKLKB1 | |
| SCHEMBL2856474 | 0.81 | F10 (0.76) | F10F2F9PLATKLKB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7745623-B2 | 1'-{(2S)-3-[(6-chloronaphthalen-2-yl)sulfonyl]-2-hydroxypropanoyl}-1,4'-bipiperidin-2-one or salts, useful as a drug for treating thrombosis | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-06-29 | — | — | US | disclosed |
| US-20100160629-A1 | CYCLIC AMIDE DERIVATIVE, AND ITS PRODUCTION AND USE | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-06-24 | — | — | US | disclosed |
| US-20080255362-A1 | 1'-{(2S)-3-[(6-chloronaphthalen-2-yl)sulfonyl]-2-hydroxypropanoyl}-1,4'-bipiperidin-2-one or salts, useful as a drug for treating thrombosis | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-10-16 | — | — | US | disclosed |
| US-20080255352-A1 | 1'-{(2S)-3-[(6-chloronaphthalen-2-yl)sulfonyl]-2-hydroxypropanoyl}-1,4'-bipiperidin-2-one or salts, useful as a drug for treating thrombosis | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-10-16 | — | — | US | disclosed |
| US-20070244118-A1 | 1'-{(2S)-3-[(6-chloronaphthalen-2-yl)sulfonyl]-2-hydroxypropanoyl}-1,4'-bipiperidin-2-one or salts, useful as a drug for treating thrombosis | TAKEDA PHARMACEUTICAL COMPANY (JP) | 2007-10-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080255352-A1 | 1'-{(2S)-3-[(6-chloronaphthalen-2-yl)sulfonyl]-2-hydroxypropanoyl}-1,4'-bipiperidin-2-one or salts, useful as a drug for treating thrombosis | JAK2, CNR1, F2 | F10 224/4885F2 3/4885F9 304/4885 |
| US-20100160629-A1 | CYCLIC AMIDE DERIVATIVE, AND ITS PRODUCTION AND USE | CNR1, CNR2, ARG1 | F10 305/4885F2 7/4885F9 240/4885 |
| US-20070244118-A1 | 1'-{(2S)-3-[(6-chloronaphthalen-2-yl)sulfonyl]-2-hydroxypropanoyl}-1,4'-bipiperidin-2-one or salts, useful as a drug for treating thrombosis | JAK2, CNR1, CNR2 | F10 232/4885F2 4/4885F9 294/4885 |
| US-20080255362-A1 | 1'-{(2S)-3-[(6-chloronaphthalen-2-yl)sulfonyl]-2-hydroxypropanoyl}-1,4'-bipiperidin-2-one or salts, useful as a drug for treating thrombosis | JAK2, CNR1, F2 | F10 224/4885F2 3/4885F9 304/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.